OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr Ghia on Safety Considerations After Fixed-Duration Ibrutinib Plus Venetoclax in CLL

September 18th 2025

Paolo Ghia, MD, PhD, discusses the safety considerations of fixed-duration ibrutinib plus venetoclax after retreatment in patients with CLL.

Catamero on Challenges of Community-Based Administration of Bispecifics and CAR T-Cell Therapy in Myeloma

September 18th 2025

Donna Catamero, ANP-BC, OCN, CCRC, discusses the challenges community-based clinicians face in delivering bispecific antibodies and CAR T-cell therapy for multiple myeloma.

Dr Gangat on Ruxolitinib as the Standard of Care in Myelofibrosis

September 18th 2025

Naseema Gangat, MBBS, discusses the JAK inhibitor ruxolitinib as the standard of care for the treatment of patients with myelofibrosis.

Dr Pal on the Rationale for Evaluating Atezolizumab in High-Risk Localized RCC

September 18th 2025

Sumanta Pal, MD, FASCO, explained the rationale for evaluating atezolizumab vs placebo for the treatment of patients with high-risk localized RCC.

Dr Mouhieddine on the Potential Predictive Role of Ferritin Levels and ALC in Bispecific Antibody–Treated Multiple Myeloma

September 17th 2025

Tarek Mouhieddine, MD, discusses the predictive role of ferritin levels and ALC in patients with multiple myeloma receiving bispecific antibodies.

Dr Raab on Updated Findings With Teclistamab-Based Induction in Newly Diagnosed Multiple Myeloma

September 17th 2025

Marc S. Raab, MD, PhD, discusses the efficacy of teclistamab-based induction in patients with newly diagnosed multiple myeloma.

Dr Chehrazi-Raffle on the TiNivo-2 Study of Tivozanib With/Without Nivolumab in mRCC

September 16th 2025

Alexander Chehrazi-Raffle, MD, discusses the rationale for a subgroup analysis of the TiNivo-2 of tivozanib with/without nivolumab in mRCC.

Dr Chahoud on the Safety of ALLO-316 in Advanced ccRCC

September 16th 2025

Jad Chahoud, MD, MPH, discusses the safety profile of ALLO-316 for the treatment of patients with advanced clear cell renal carcinoma.

Dr Arora on the Associations Between Income/Race and MCL Survival Outcomes

September 15th 2025

Ruby Arora, MD, discusses a study investigating survival outcomes and sociodemographic disparities among patients with MCL from 2000 to 2021.

Dr Dorritie on the Use of Pirtobrutinib Following Prior BTK Inhibition in CLL

September 15th 2025

Kathleen A. Dorritie, MD, discusses data that inform the use of pirtobrutinib and liso-cel for the treatment of patients with chronic lymphocytic leukemia.

Dr Eroglu on the Role of Triplet vs Doublet Regimens in Melanoma With Symptomatic Brain Metastases

September 15th 2025

Zeynep Eroglu, MD, discusses the implications of using triplet vs doublet regimens in patients with melanoma who have symptomatic brain metastases.

Dr Moore on the Evolution of Treatment Strategies for Advanced Endometrial Cancer

September 12th 2025

Kathleen N. Moore, MD, MS, discusses how standard-of-care treatment strategies for advanced recurrent endometrial cancer have improved over time.

Dr Jacob on the FDA Approval of the Gemcitabine Intravesical System for NMIBC

September 11th 2025

Joseph Jacob, MD, MCR, discusses the FDA approval of the gemcitabine intravesical system for patients with BCG-unresponsive NMIBC with carcinoma in situ.

Dr Moore on the Present Standing of PARP Inhibitors in Ovarian Cancer

September 10th 2025

Kathleen N. Moore, MD, MS, discusses the use of PARP inhibitors in patients with ovarian cancer.

Dr Schlechter on the Safety of Botensilimab Plus Balstilimab in Pretreated MSS CRC

September 10th 2025

Benjamin L. Schlechter, MD, discusses safety with botensilimab plus balstilimab in MSS CRC.

Dr Kuykendall on Quality of Life Outcomes With Rusfertide in Polycythemia Vera

September 10th 2025

Andrew Kuykendall, MD, details the benefit of rusfertide regarding quality of life in patients with polycythemia vera compared with placebo.

Dr Necchi on the Design of the Phase 2 SURE-02 Study Assessing Pembrolizumab/Sacituzumab Govitecan in Muscle-Invasive Bladder Cancer

September 10th 2025

Andrea Necchi, MD, discusses the design of the SURE-02 study evaluating pembrolizumab plus sacituzumab govitecan in muscle-invasive bladder cancer.

Dr Mouabbi on Data From the CompassHER2 pCR Trial in HER2+ Breast Cancer

September 9th 2025

Jason Aboudi Mouabbi, MD, discusses neoadjuvant multi-agent chemotherapy in HER2+ breast cancer.

Dr Chahoud on ALLO-316 in Advanced Clear Cell Renal Cell Carcinoma

September 9th 2025

Jad Chahoud, MD, MPH, discusses the CAR T-cell therapy ALLO-316 in advanced clear cell renal carcinoma (ccRCC).

Dr Xia on the Differences Between ctDNA Monitoring Strategies in MET Exon 14–Mutant NSCLC

September 9th 2025

Yang Xia, MD, PhD, discusses the use of different ctDNA monitoring to detect resistance and predict outcomes in NSCLC with MET exon 14 skipping mutations.